158 related articles for article (PubMed ID: 9815747)
1. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.
Adjei AA; Budihardjo II; Rowinsky EK; Kottke TJ; Svingen PA; Buckwalter CA; Grochow LB; Donehower RC; Kaufmann SH
Clin Cancer Res; 1997 May; 3(5):761-70. PubMed ID: 9815747
[TBL] [Abstract][Full Text] [Related]
2. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.
Adjei AA; Charron M; Rowinsky EK; Svingen PA; Miller J; Reid JM; Sebolt-Leopold J; Ames MM; Kaufmann SH
Clin Cancer Res; 1998 Mar; 4(3):683-91. PubMed ID: 9533538
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Bible KC; Kaufmann SH
Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
[TBL] [Abstract][Full Text] [Related]
4. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells.
Liebmann JE; Fisher J; Teague D; Cook JA
Oncol Res; 1994; 6(1):25-31. PubMed ID: 7919549
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
Kaufmann SH; Peereboom D; Buckwalter CA; Svingen PA; Grochow LB; Donehower RC; Rowinsky EK
J Natl Cancer Inst; 1996 Jun; 88(11):734-41. PubMed ID: 8637027
[TBL] [Abstract][Full Text] [Related]
6. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.
Adjei AA; Davis JN; Bruzek LM; Erlichman C; Kaufmann SH
Clin Cancer Res; 2001 May; 7(5):1438-45. PubMed ID: 11350915
[TBL] [Abstract][Full Text] [Related]
7. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
Foroodi F; Duivenvoorden WC; Singh G
Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience.
Albain KS; Swinnen LJ; Erickson LC; Stiff PJ; Fisher SG; Fisher RI
Semin Oncol; 1992 Jun; 19(3 Suppl 9):102-9. PubMed ID: 1641650
[TBL] [Abstract][Full Text] [Related]
9. Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
Strawn LM; Kabbinavar F; Schwartz DP; Mann E; Shawver LK; Slamon DJ; Cherrington JM
Clin Cancer Res; 2000 Jul; 6(7):2931-40. PubMed ID: 10914743
[TBL] [Abstract][Full Text] [Related]
10. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells.
Bible KC; Kaufmann SH
Cancer Res; 1996 Nov; 56(21):4856-61. PubMed ID: 8895733
[TBL] [Abstract][Full Text] [Related]
11. 1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking.
Swinnen LJ; Barnes DM; Fisher SG; Albain KS; Fisher RI; Erickson LC
Cancer Res; 1989 Mar; 49(6):1383-9. PubMed ID: 2924295
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.
Barret JM; Kruczynski A; Etiévant C; Hill BT
Cancer Chemother Pharmacol; 2002 Jun; 49(6):479-86. PubMed ID: 12107553
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol binds to duplex DNA.
Bible KC; Bible RH; Kottke TJ; Svingen PA; Xu K; Pang YP; Hajdu E; Kaufmann SH
Cancer Res; 2000 May; 60(9):2419-28. PubMed ID: 10811119
[TBL] [Abstract][Full Text] [Related]
15. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
Bible KC; Boerner SA; Kirkland K; Anderl KL; Bartelt D; Svingen PA; Kottke TJ; Lee YK; Eckdahl S; Stalboerger PG; Jenkins RB; Kaufmann SH
Clin Cancer Res; 2000 Feb; 6(2):661-70. PubMed ID: 10690552
[TBL] [Abstract][Full Text] [Related]
16. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
Papadopoulou MV; Bloomer WD
In Vivo; 2007; 21(2):175-80. PubMed ID: 17436565
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of DNA-reactive antineoplastic agents and protection against S-phase-specific agents by anguidine in Chinese hamster ovary cells.
Hromas R; Barlogie B; Swartzendruber D; Drewinko B
Cancer Res; 1983 Jul; 43(7):3070-3. PubMed ID: 6189590
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
[TBL] [Abstract][Full Text] [Related]
20. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice.
Elliott WL; Howard CT; Dykes DJ; Leopold WR
Cancer Res; 1989 Oct; 49(20):5586-90. PubMed ID: 2477146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
